Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9897525 | 0.90 | MAPT (0.33) | MAPTCHRNB2CHRNA4 | |
| SCHEMBL9897825 | 0.84 | KDM4E (0.33) | MAPT | |
| SCHEMBL9898815 | 0.84 | KDM4E (0.33) | MAPT | |
| SCHEMBL9898104 | 0.77 | MAPT (0.32) | MAPTCHRNB2CHRNA4 | |
| SCHEMBL9898631 | 0.76 | — | — | |
| Dymanthine SCHEMBL1899930 | 0.75 | DNM1 (0.52) | — | |
| SCHEMBL37352 | 0.75 | LMNA (0.40) | — | |
| SCHEMBL4751094 | 0.74 | MAPT (0.34) | MAPT | |
| SCHEMBL11225639 | 0.74 | LMNA (0.33) | — | |
| SCHEMBL55866 | 0.74 | LMNA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150595-B2 | Process for producing silane coupling agent | BRIDGESTONE CORPORATION (JP) | 2015-10-06 | — | — | US | claimed |
| EP-2471798-B1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | BRIDGESTONE CORP (JP) | 2015-08-19 | — | — | EP | claimed |
| EP-2471798-A1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | Bridgestone Corporation (JP) | 2012-07-04 | — | — | EP | claimed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | claimed |
| US-9150595-B2 | Process for producing silane coupling agent | BRIDGESTONE CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2471798-B1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | BRIDGESTONE CORP (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2471798-A1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | Bridgestone Corporation (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | HAO2, SAMM50, SKP2 | MAPT 3581/4885CHRNB2 4717/4885CHRNA4 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.